Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae

Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) metho...

Full description

Bibliographic Details
Published in:Journal of Infection in Developing Countries
Main Authors: Fernando Pasteran, Celeste Lucero, Melina Rapoport, Leonor Guerriero, Irene Barreiro, Ezequiel Albornoz, Omar Veliz, Alejandra Corso
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2012-02-01
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/2238
_version_ 1849412141372669952
author Fernando Pasteran
Celeste Lucero
Melina Rapoport
Leonor Guerriero
Irene Barreiro
Ezequiel Albornoz
Omar Veliz
Alejandra Corso
author_facet Fernando Pasteran
Celeste Lucero
Melina Rapoport
Leonor Guerriero
Irene Barreiro
Ezequiel Albornoz
Omar Veliz
Alejandra Corso
author_sort Fernando Pasteran
collection DOAJ
container_title Journal of Infection in Developing Countries
description Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) methods as zone breakpoints are not available for the disc diffusion technique. Methodology: Clinical and Laboratory Standards Institute methods for agar dilution and disc diffusion were compared to determine tentative zone breakpoints that best correlate to tigecycline and i.v. fosfomycin MIC breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing. A total of 195 Enterobacteriaceae with defined mechanisms of resistance were tested in duplicate assays. Half of the strains were characterized as carbapenemase producers (KPC-2, OXA-48, OXA-163, VIM-1, VIM-2, IMP-8, NDM-1). Results: Corresponding zone diameters of susceptible ≥15mm, resistant ≤12mm and susceptible ≥17mm, resistant ≤15mm for the 50µg fosfomycin plus 50µg glucose-6-phosphate and 200µg fosfomycin plus 50µg glucose-6-phosphate discs, respectively, allowed categorization of the strains with an acceptable level of error (< 10% minor errors, < 1.5 % major errors, < 1% very major errors and categorical agreement > 90%). For the 15µg tigecycline disc, the best performance was achieved with the corresponding zone diameters of susceptible ≥ 21mm and resistant ≤ 16mm, which eliminated the very major and major errors but not the minor errors (34.4%). Conclusions: Based on these results, tigecycline and fosfomycin can be included in the routine panel of antibiotics for susceptibility testing by disc diffusion to provide fast and reliable information for the selection of treatment alternatives, especially for strains with extreme resistance, as carbapenemase producers.
format Article
id doaj-art-559dba781b7f4382a75bec2fdffaf94c
institution Directory of Open Access Journals
issn 1972-2680
language English
publishDate 2012-02-01
publisher The Journal of Infection in Developing Countries
record_format Article
spelling doaj-art-559dba781b7f4382a75bec2fdffaf94c2025-08-20T03:48:58ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802012-02-0160510.3855/jidc.2238Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for EnterobacteriaceaeFernando Pasteran0Celeste Lucero1Melina Rapoport2Leonor Guerriero3Irene Barreiro4Ezequiel Albornoz5Omar Veliz6Alejandra Corso7Instituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, ArgentinaInstituto Nacional de Enfermedades Infecciosas (INEI)- ANLIS “Dr. Carlos G. Malbrán”, Ministerio de Salud y Ambiente, Ciudad Autónoma de Buenos Aires, Argentina Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) methods as zone breakpoints are not available for the disc diffusion technique. Methodology: Clinical and Laboratory Standards Institute methods for agar dilution and disc diffusion were compared to determine tentative zone breakpoints that best correlate to tigecycline and i.v. fosfomycin MIC breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing. A total of 195 Enterobacteriaceae with defined mechanisms of resistance were tested in duplicate assays. Half of the strains were characterized as carbapenemase producers (KPC-2, OXA-48, OXA-163, VIM-1, VIM-2, IMP-8, NDM-1). Results: Corresponding zone diameters of susceptible ≥15mm, resistant ≤12mm and susceptible ≥17mm, resistant ≤15mm for the 50µg fosfomycin plus 50µg glucose-6-phosphate and 200µg fosfomycin plus 50µg glucose-6-phosphate discs, respectively, allowed categorization of the strains with an acceptable level of error (< 10% minor errors, < 1.5 % major errors, < 1% very major errors and categorical agreement > 90%). For the 15µg tigecycline disc, the best performance was achieved with the corresponding zone diameters of susceptible ≥ 21mm and resistant ≤ 16mm, which eliminated the very major and major errors but not the minor errors (34.4%). Conclusions: Based on these results, tigecycline and fosfomycin can be included in the routine panel of antibiotics for susceptibility testing by disc diffusion to provide fast and reliable information for the selection of treatment alternatives, especially for strains with extreme resistance, as carbapenemase producers. https://jidc.org/index.php/journal/article/view/2238Tigecylcinefosfomycindisc diffusionKPCcarbapenemase
spellingShingle Fernando Pasteran
Celeste Lucero
Melina Rapoport
Leonor Guerriero
Irene Barreiro
Ezequiel Albornoz
Omar Veliz
Alejandra Corso
Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
Tigecylcine
fosfomycin
disc diffusion
KPC
carbapenemase
title Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
title_full Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
title_fullStr Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
title_full_unstemmed Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
title_short Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
title_sort tigecycline and intravenous fosfomycin zone breakpoints equivalent to the eucast mic criteria for enterobacteriaceae
topic Tigecylcine
fosfomycin
disc diffusion
KPC
carbapenemase
url https://jidc.org/index.php/journal/article/view/2238
work_keys_str_mv AT fernandopasteran tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT celestelucero tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT melinarapoport tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT leonorguerriero tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT irenebarreiro tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT ezequielalbornoz tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT omarveliz tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae
AT alejandracorso tigecyclineandintravenousfosfomycinzonebreakpointsequivalenttotheeucastmiccriteriaforenterobacteriaceae